Navigation Links
Sangamo BioSciences to Present at the Bank of America 2008 Healthcare Conference
Date:5/9/2008

RICHMOND, Calif., May 7 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 7:40 p.m. (ET) on Tuesday, May 13, 2008 at the Bank of America Healthcare Conference in Las Vegas.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFTM) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNTM) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology news :

1. Inaugural Kirkham Gold Medal presented to expert on soil physics
2. Reflecting on the social implications of human genetics research -- past, present and future
3. 2008 Signature Genomic Laboratories Travel Award presented
4. Womens health-related scientific findings presented by University of Pittsburgh researchers
5. Arbor Vita rapid H5N1 flu diagnostic presented at ICEID meeting
6. Pioneers in small RNA research to present at UD symposium, April 16
7. Climate change in the Baltic Sea basin -- past, present and future
8. Internationally recognized experts presents a complete overview on hydroecology and ecohydrology
9. Roger Kornberg to present lecture at the Joint Biophysical Society/IUPAB Meeting
10. Present-day species of piranha result from a marine incursion into the Amazon Basin
11. New book presents methods to poke and prod individual molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... ... June 22, 2017 , ... AESKU.GROUP, an ... Diagnostische Systeme & Technologien GmbH, thereby expanding its product portfolio to include allergy ... fever, urticaria, asthma, atopic eczema or a food allergy. Allergies are escalating to ...
(Date:6/22/2017)... ... June 22, 2017 , ... RURO, ... of Limfinity® version 6.5, a content-packed update to the Limfinity® framework. , LimitLIS® ... larger and more diverse base of customers among labs and other businesses. Limfinity® ...
(Date:6/20/2017)... , June 20, 2017  Kibow Biotech Inc., ... to announce the issuance of a new patent covering ... hyperuricemia by the U.S. Patent and Trademark Office on ... winner of the Buzz of Bio award in 2014 ... akin to developing non-drug approaches to chronic disease. Renadyl™, ...
(Date:6/19/2017)... ... 19, 2017 , ... EDETEK, Inc., a clinical technology company ... launching two new additions of its award-winning cloud-based platform CONFORM™: Information Hub and ... 2017 Annual Meeting in Chicago, IL, June 19-22, 2017. , “Modern clinical trials ...
Breaking Biology Technology: